A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
NCT05818683
This study is recruiting at 7 US sites in 5 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to identify the recommended phase 2 regimen(s) RP2R(s) of pasritamig and combination regimens in Part 1 (dose escalation) and to determine safety at the putative RP2R(s) of pasritamig with the combination regimens in Part 2 (dose expansion).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Metastatic Castration-resistant Prostate Neoplasms
- Metastatic Hormone-sensitive Prostate Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- Janssen Research & Development, LLC
- Last updated on ClinicalTrials.gov
- September 25, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 1
- Florida Cancer Specialists · Sarasota, FL
Michigan · 1
- Start Midwest · Grand Rapids, MI
Missouri · 1
- Washington University School Of Medicine · St Louis, MO
New York · 3
- Perlmutter Cancer Center at NYU Langone Brooklyn · Brooklyn, NY
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island · Mineola, NY
- NYU Langone Health · New York, NY
Pennsylvania · 1
- Sidney Kimmel Cancer Center - Jefferson Health · Philadelphia, PA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.